机构投资者在获得丰厚的收入并提出了2025年的指导意见之后,增加了或维持了辉瑞公司的股权。 Institutional investors increased or maintained Pfizer stakes after strong earnings and raised 2025 guidance.

包括Relyea Zuckerberg Hanson LLC、KLP Kapitalforvalting AS、CFM财富伙伴LLC和Hardy Reed LLC在内的机构投资者最近改变了其Pfizer Inc(PFE)的股份,几家股份增加或维持。 Institutional investors including Relyea Zuckerberg Hanson LLC, KLP Kapitalforvaltning AS, CFM Wealth Partners LLC, and Hardy Reed LLC made recent changes to their Pfizer Inc. (PFE) holdings, with several increasing or maintaining stakes. Pfizer报告,8月5日第二季度收入丰厚,贴上0.78美元EPS——大大高于58美元的估计数——收入为14.65亿美元,比同年增加10.3%。 Pfizer reported strong second-quarter earnings on August 5, posting $0.78 EPS—well above the $0.58 estimate—with $14.65 billion in revenue, up 10.3% year-over-year. 该公司将其2025年全年EPS指导提高到2.90至3.10美元。 The company raised its 2025 full-year EPS guidance to $2.90–$3.10. 股票交易额约为26.45美元,市场上限为1 50.38亿美元,P/E比率为14.07,协商一致的“稳住”评级和28.41美元平均价格目标。 Shares traded around $26.45, with a market cap of $150.38 billion, a P/E ratio of 14.07, and a consensus "Hold" rating and $28.41 average price target. 该存货的52周范围为20.92美元至30.43美元。 The stock has a 52-week range of $20.92 to $30.43.